Cargando…
Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol
BACKGROUND: There is limited evidence on whether screening for type 2 diabetes mellitus affects health outcomes. A recent systematic review of randomised clinical trials found only one trial that met their inclusion criteria; therefore, current guidelines for screening interventions for type 2 diabe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359237/ https://www.ncbi.nlm.nih.gov/pubmed/32660625 http://dx.doi.org/10.1186/s13643-020-01417-3 |
_version_ | 1783559006309056512 |
---|---|
author | Mearns, Helen Otiku, Paul Kuodi Shelton, Mary Kredo, Tamara Kagina, Benjamin M. Schmidt, Bey-Marrié |
author_facet | Mearns, Helen Otiku, Paul Kuodi Shelton, Mary Kredo, Tamara Kagina, Benjamin M. Schmidt, Bey-Marrié |
author_sort | Mearns, Helen |
collection | PubMed |
description | BACKGROUND: There is limited evidence on whether screening for type 2 diabetes mellitus affects health outcomes. A recent systematic review of randomised clinical trials found only one trial that met their inclusion criteria; therefore, current guidelines for screening interventions for type 2 diabetes mellitus are based on expert opinions and best practice rather than synthesised evidence. This systematic review seeks to collate evidence from non-randomised studies to investigate the effect of screening for adults with type 2 diabetes on outcomes including diabetes-related morbidity, mortality (all-cause and diabetes-related) and harms. METHODS: This systematic review will follow Effective Practice and Organisation of Care (EPOC) guidelines for the synthesis of non-randomised studies. We will search PubMed/MEDLINE, Scopus, Web of Science, CINAHL, Academic Search Premier and Health Source Nursing Academic (from inception onwards). We will include non-randomised trials, controlled before-after studies, interrupted time-series studies, repeated measures studies and concurrently controlled prospective cohort studies. The primary outcome will be diabetes-related morbidity (microvascular complications of diabetic retinopathy, nephropathy or neuropathy or macrovascular complications of non-fatal myocardial infarction, peripheral arterial disease or non-fatal stroke). The secondary outcomes will be mortality (all-cause and diabetes-related) and harms of screening strategies to patients (including psychological harms or adverse events following treatments) or to health care system (including resource allocation for false-positives or overdiagnosis). Two reviewers will independently screen all citations and full-text articles. Data will be abstracted by one reviewer and checked by a second. The risk of bias of individual studies will be appraised using the ROBINS-I tool. GRADE will be used to determine the quality of the scientific evidence. If feasible, we will conduct random effects meta-analysis where appropriate. If necessary, analyses will be conducted to explore the potential sources of heterogeneity (e.g. age, sex, socio-economic status, rural versus urban or low-middle income versus high-income country). We will disseminate the findings via publications and through relevant networks. DISCUSSION: The protocol outlines the methods for systematically reviewing and synthesising evidence of screening strategies for type 2 diabetes mellitus and their effect on health outcomes associated with the disease. The potential impact of this systematic review is improved evidence-informed decision-making for policies and practice for screening of type-2 diabetes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020147439 |
format | Online Article Text |
id | pubmed-7359237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73592372020-07-17 Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol Mearns, Helen Otiku, Paul Kuodi Shelton, Mary Kredo, Tamara Kagina, Benjamin M. Schmidt, Bey-Marrié Syst Rev Protocol BACKGROUND: There is limited evidence on whether screening for type 2 diabetes mellitus affects health outcomes. A recent systematic review of randomised clinical trials found only one trial that met their inclusion criteria; therefore, current guidelines for screening interventions for type 2 diabetes mellitus are based on expert opinions and best practice rather than synthesised evidence. This systematic review seeks to collate evidence from non-randomised studies to investigate the effect of screening for adults with type 2 diabetes on outcomes including diabetes-related morbidity, mortality (all-cause and diabetes-related) and harms. METHODS: This systematic review will follow Effective Practice and Organisation of Care (EPOC) guidelines for the synthesis of non-randomised studies. We will search PubMed/MEDLINE, Scopus, Web of Science, CINAHL, Academic Search Premier and Health Source Nursing Academic (from inception onwards). We will include non-randomised trials, controlled before-after studies, interrupted time-series studies, repeated measures studies and concurrently controlled prospective cohort studies. The primary outcome will be diabetes-related morbidity (microvascular complications of diabetic retinopathy, nephropathy or neuropathy or macrovascular complications of non-fatal myocardial infarction, peripheral arterial disease or non-fatal stroke). The secondary outcomes will be mortality (all-cause and diabetes-related) and harms of screening strategies to patients (including psychological harms or adverse events following treatments) or to health care system (including resource allocation for false-positives or overdiagnosis). Two reviewers will independently screen all citations and full-text articles. Data will be abstracted by one reviewer and checked by a second. The risk of bias of individual studies will be appraised using the ROBINS-I tool. GRADE will be used to determine the quality of the scientific evidence. If feasible, we will conduct random effects meta-analysis where appropriate. If necessary, analyses will be conducted to explore the potential sources of heterogeneity (e.g. age, sex, socio-economic status, rural versus urban or low-middle income versus high-income country). We will disseminate the findings via publications and through relevant networks. DISCUSSION: The protocol outlines the methods for systematically reviewing and synthesising evidence of screening strategies for type 2 diabetes mellitus and their effect on health outcomes associated with the disease. The potential impact of this systematic review is improved evidence-informed decision-making for policies and practice for screening of type-2 diabetes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020147439 BioMed Central 2020-07-13 /pmc/articles/PMC7359237/ /pubmed/32660625 http://dx.doi.org/10.1186/s13643-020-01417-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Protocol Mearns, Helen Otiku, Paul Kuodi Shelton, Mary Kredo, Tamara Kagina, Benjamin M. Schmidt, Bey-Marrié Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
title | Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
title_full | Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
title_fullStr | Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
title_full_unstemmed | Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
title_short | Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
title_sort | screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359237/ https://www.ncbi.nlm.nih.gov/pubmed/32660625 http://dx.doi.org/10.1186/s13643-020-01417-3 |
work_keys_str_mv | AT mearnshelen screeningstrategiesforadultswithtype2diabetesmellitusasystematicreviewprotocol AT otikupaulkuodi screeningstrategiesforadultswithtype2diabetesmellitusasystematicreviewprotocol AT sheltonmary screeningstrategiesforadultswithtype2diabetesmellitusasystematicreviewprotocol AT kredotamara screeningstrategiesforadultswithtype2diabetesmellitusasystematicreviewprotocol AT kaginabenjaminm screeningstrategiesforadultswithtype2diabetesmellitusasystematicreviewprotocol AT schmidtbeymarrie screeningstrategiesforadultswithtype2diabetesmellitusasystematicreviewprotocol |